These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30790602)

  • 1. Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study.
    Torres T; Balato A; Conrad C; Conti A; Dapavo P; Ferreira P; Gaiani F; Leite L; Malagoli P; Mendes-Bastos P; Megna M; Messina F; Nidegger A; Odorici G; Piaserico S; Prignano F; Ribero S; Ricceri F; Tonini A; Valério J; Chiricozzi A
    J Am Acad Dermatol; 2019 Jul; 81(1):273-275. PubMed ID: 30790602
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world drug survival of ixekizumab for psoriasis.
    Lee EB; Pithadia DJ; Reynolds KA; Reddy SP; Egeberg A; Wu JJ
    J Am Acad Dermatol; 2019 Jul; 81(1):270-272. PubMed ID: 30690047
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.
    Egeberg A; Bryld LE; Skov L
    J Am Acad Dermatol; 2019 Jul; 81(1):173-178. PubMed ID: 30914343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Am Acad Dermatol; 2018 Jul; 79(1):155-157. PubMed ID: 29307635
    [No Abstract]   [Full Text] [Related]  

  • 5. Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
    Chiricozzi A; Conti A; Burlando M; Odorici G; Gaiani F; Panduri S; Malagoli P
    Dermatology; 2019; 235(3):213-218. PubMed ID: 30928971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study.
    Georgakopoulos JR; Ighani A; Phung M; Yeung J
    J Am Acad Dermatol; 2018 May; 78(5):1019-1020. PubMed ID: 29180095
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
    Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
    J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study.
    van den Reek JMPA; van Vugt LJ; van Doorn MBA; van der Kraaij GE; de Kort WJA; Lucker GPH; Horvath B; Njoo MD; Bovenschen HJ; Ossenkoppele PM; De Bruin-Weller MS; de Groot M; Mommers R; Prevoo RLMA; van de Kerkhof PCM; Spuls PI; Kievit W; de Jong EMGJ
    Acta Derm Venereol; 2018 Jul; 98(7):648-654. PubMed ID: 29405245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
    Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience.
    Momose M; Asahina A; Umezawa Y; Nakagawa H
    J Dermatol; 2018 Mar; 45(3):318-321. PubMed ID: 29194723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
    Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.
    Georgakopoulos JR; Ighani A; Zhou LL; Yeung J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e32-e34. PubMed ID: 28695989
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
    Qiang JK; Shahbaz A; Kim W; Marinas J; Greaves S; Yeung J
    J Am Acad Dermatol; 2016 Jan; 74(1):176-7. PubMed ID: 26702799
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study.
    Saraceno R; Specchio F; Torres T; Nisticò SP; Rizza S; Chimenti S
    J Am Acad Dermatol; 2012 May; 66(5):e180-2. PubMed ID: 22507590
    [No Abstract]   [Full Text] [Related]  

  • 16. Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.
    Ohtsuki M; Morita A; Igarashi A; Imafuku S; Tada Y; Fujita H; Fujishige A; Yamaguchi M; Teshima R; Tani Y; Nakagawa H
    J Dermatol; 2017 Oct; 44(10):1105-1111. PubMed ID: 28543617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment on "Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study".
    Palacios-García L; Gómez-de Castro C; Mir-Bonafé M; Calzón C; Galache C; Santos-Juanes J
    J Am Acad Dermatol; 2019 Sep; 81(3):e81-e82. PubMed ID: 31112727
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to: "Comment on 'Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study'".
    Chiricozzi A; Torres T
    J Am Acad Dermatol; 2019 Sep; 81(3):e83. PubMed ID: 31112724
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain.
    Notario J; Deza G; Vilarrasa E; Valentí F; Muñoz C; Mollet J; Rocamora V; Carrascosa JM; Del Alcázar E; Alsina M; Vidal D; Puig L; López-Ferrer A; Riera J; Gallardo F; Ferran M
    J Dermatolog Treat; 2019 Aug; 30(5):424-429. PubMed ID: 30244618
    [No Abstract]   [Full Text] [Related]  

  • 20. Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission.
    Bellinato F; Girolomoni G; Gisondi P
    Br J Dermatol; 2019 Dec; 181(6):1319-1320. PubMed ID: 31209871
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.